Menu Search
Equities

Falco Holdings Co Ltd

FALHF:PKL

Falco Holdings Co Ltd

Actions
  • Price (USD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FALCO HOLDINGS Co.,Ltd is a Japan-based company mainly engaged in the clinical testing business and the dispensing pharmacy business. The Company operates in two business segments. The Clinical Testing segment is engaged in the contracted clinical specimen testing business for hospitals and clinics, as well as the development and sale of electronic medical charts and other medical information systems, and the wholesale of in-vitro diagnostic drugs. The Dispensing Pharmacy segment is engaged in the operation of dispensing pharmacies.

  • Revenue in JPY (TTM)43.01bn
  • Net income in JPY1.67bn
  • Incorporated1982
  • Employees1.16k
  • Location
    Falco Holdings Co Ltd1-3-7, Uchihirano-machi, Nakagyo-kuOSAKA-SHI 540-0037JapanJPN
  • Phone+81 676326150
  • Fax+81 752578511
  • Websitehttps://www.falco-hd.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.